Xencor, Inc.
- XNCR
- NASDAQ
- Biotechnology
- Antibody Engineering (Bispecifics)
- Cytokine Therapeutics
- Cancer Immunotherapy
$22.85
Today −4.79%Quote Oct 16, 2026, 08:00 PM UTC
−7.08%over the last month
Max drawdown −10.8%From 1-month high −10.8%3 months +21.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.70B
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$34.40
+50.5% from here
Floor
$22.78
0.3% below price
Where the price sits
28 analysts
Analyst range, low to high
$20.00$46.00
- Price $22.85
- Resistance $24.41
- Consensus $34.40
The price is just above its floor. Analysts' average target sits about 51% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about XNCRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $51.2M
- Royalty$41.2M80.5%
- Milestone$10.0M19.5%
Industry
Biotechnology
Employees
260